Windlas Biotech Limited has issued a notice regarding a scheduled meeting of its Board of Directors. The meeting is set to take place on Thursday, November 5, 2026.
The primary purpose of this board meeting is to consider and approve the company's unaudited standalone financial results for the quarter and half year ended September 30, 2026. This disclosure is made pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company also confirmed that its trading window for designated persons has been closed since October 1, 2026, in accordance with the company's code of conduct under SEBI (Prohibition of Insider Trading) Regulations 2015. This closure was previously communicated via a letter dated September 25, 2026.
The trading window will remain closed until 48 hours after the declaration of the financial results to the public, after which it will reopen.
The notice was signed by Ananta Narayan Panda, Company Secretary & Compliance Officer, and addressed to the listing/compliance departments of both BSE Limited and National Stock Exchange of India Limited.